PBMs
FTC Report Reveals Big 3 PBMs Made $7.3 Billion from Excessive Markups on Specialty Generic Drugs
FTC report, Big 3 PBMs, Specialty generic drugs, Price markups, Healthcare costs, Pharmacy benefit managers
Congress Eyes Major PBM Reforms in Year-End Spending Bill
Pharmacy Benefit Managers (PBMs), PBM reforms, healthcare costs, year-end spending bill, Congress, bipartisan legislation, transparency, drug prices.
Senators Wyden and Brown Urge FTC to Expand Investigation into PBMs’ Anti-Competitive Practices
Pharmacy Benefit Managers (PBMs), Anti-Competitive Practices, FTC Investigation, Co-Manufacturing Agreements, Drug Prices, Healthcare Reform
Novo Nordisk CEO Faces Senate Scrutiny Over High Prices of Ozempic and Wegovy
Novo Nordisk, Senate Hearing, Ozempic, Wegovy, Drug Prices, Pharmacy Benefit Managers (PBMs), Insurance Coverage, Healthcare System
Cigna Challenges FTC’s Report on Pharmacy Benefit Managers, Alleging Unconstitutional Actions and Misleading Claims
Cigna, FTC, Pharmacy Benefit Managers (PBMs), Express Scripts, Unconstitutional Report, Misleading Claims, Drug Prices, Healthcare System
PhRMA Intensifies Pricing Criticism, Targets Shared Ownership of Insurers and PBMs in New Ad
PhRMA, pricing attack, shared ownership, insurers, PBMs, new ad
FTC to Sue Major PBMs Over Insulin and Drug Prices Amid Anticompetitive Concerns
FTC, PBMs, Insulin Prices, Drug Prices, Anticompetitive Practices, Pharmacy Benefit Managers, Health Companies, Legal Action